In Silico Designing of Triazolothiadiazine as Anticancer Agents

Authors

  • Monika Kakadiya Shree Dhanvatary Pharmacy college, kim
  • Nidhi Joshi
  • Malleshappa Noolvi
  • Uttam A. More

Abstract

Cancer is irregular growth of cells and formation of tumor. There are approximately 9.6 million death reported globally. It is caused by physical or genetic factor. There are various targets for the inhibition of growth of cancerous cells. Inhibition of colchicines binding site of tubulin is promising target in field of cancer management. In this study, we designed 25 novel thiazole and triazolothiadiazine derivatives as colchicine binding site inhibitors and docked in 1SA0 pdb file. In docking study PM-10, PM-6 showed similar hydrogen bond interaction as CA-4 and WX-132 showed. PM-17, PM-18, PM-25 show highest energy docking score and showed better ADMET profile. The ADMET prediction and docking study of novel designed molecules revealed that PM-17, PM-18, PM-25, PM-6, PM-10 may inhibit Colchicines binding site of Tubulin with good potential.

 

Keywords: Cancer, tubulin destabilizing agent, triazolothiadiazine, thiazole

Cite this Article

Monika Kakadiya, Nidhi Joshi, Malleshappa Noolvi, Uttam A. More. In Silico Designing of Triazolothiadiazine as Anticancer Agents. Research & Reviews: A Journal of Drug Design & Discovery. 2019; 6(1): 10–20p.

Author Biography

  • Monika Kakadiya, Shree Dhanvatary Pharmacy college, kim
    Department of pharmaceutical chemistry

Downloads

Published

2019-05-17

Issue

Vol. 6 No. 1 (2019)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.